Q2 2026 13F · SEC CIK 1856083

Deep Track Capital, LP

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $6.8B
Reported positions: 66
Top holdings a year, 3 yrs: +33.8%
Assets under management: $8.4B

Deep Track Capital, LP is a hedge fund that reported 66 positions worth $6.8B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Guardant Health Inc (GH, 7.5%), Immunovant Inc (IMVT, 5.3%), Structure Therapeutics F Unspo (GPCR, 3.7%). A portfolio copying its top holdings returned 33.8% a year over the last 3 years, against 20.4% for the S&P 500.

Deep Track Capital, LP holdings largest 50 of 66 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Deep Track Capital, LP 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
GHGuardant Health Inc	7.5%	6.4%	3,393,312	+1.6%	$509.1M
IMVTImmunovant Inc	5.3%	5.9%	9,341,151	-19.0%	$359.9M
GPCRStructure Therapeutics F Unspo	3.7%	4.3%	4,740,072	+10.8%	$254.4M
PCVXVaxcyte Inc	3.7%	5.2%	4,300,000	+0.0%	$250.0M
ALNYAlnylam Pharmaceuticals Inc	3.7%	—	825,000	—	$248.3M
MANEVeradermics Inc	3.6%	0.7%	2,000,000	+300.0%	$245.9M
TARSTarsus Pharmaceuticals Inc	3.4%	5.2%	3,666,768	+1.9%	$230.8M
NUVLNuvalent Inc	3.2%	2.9%	1,783,322	+29.6%	$220.2M
ALKSAlkermes PLC	3.1%	2.6%	4,000,000	+11.4%	$209.6M
OCULOcular Therapeutix Inc	2.8%	3.4%	19,686,282	+0.0%	$193.3M
BMRNBiomarin Pharmaceutical Inc	2.8%	1.3%	3,307,481	+187.6%	$189.3M
NRIXNurix Therapeutics Inc	2.8%	2.0%	7,736,455	+21.9%	$187.7M
ORKAOruka Therapeutics Inc	2.7%	2.1%	1,926,000	-5.3%	$183.3M
ALMSAlumis Ord	2.6%	3.1%	6,348,558	-6.3%	$178.6M
IONSIonis Pharmaceuticals Inc	2.6%	3.0%	2,200,000	+12.8%	$174.4M
CMPSCompass Pathways PLC	2.5%	1.4%	12,161,496	+0.0%	$172.1M
VERAVera Therapeutics Inc Class A	2.5%	3.4%	4,000,000	-2.6%	$171.6M
AXSMAxsome Therapeutics, Inc.	2.5%	3.8%	700,000	-36.4%	$171.3M
GMABGenmab A/s	2.3%	2.0%	5,650,000	+54.2%	$155.2M
MLTXMoonlake Immunotherapeutics	2.0%	2.5%	6,999,025	+9.2%	$136.3M
COAGHemab Therapeutics Holdings Inc	1.9%	—	3,602,093	—	$132.3M
TNGXTango Therapeutics Inc	1.9%	1.2%	4,200,000	+52.7%	$131.3M
24477V105Definium Therapeutics Inc	1.9%	1.2%	2,750,000	-8.3%	$129.4M
GRALGRAIL, Inc.	1.8%	1.8%	1,834,944	+6.5%	$125.3M
BCAXBicara Therapeutics Inc	1.8%	1.7%	4,100,000	+0.9%	$121.7M
MAZEMaze Therapeutics Inc	1.6%	2.1%	3,732,569	+7.3%	$111.4M
CLDXCelldex Therapeutics Inc New	1.6%	0.8%	2,939,151	+128.9%	$109.4M
LBRXLB Pharmaceuticals, Inc.	1.6%	1.7%	3,352,804	+0.0%	$108.8M
MBXMbx Biosciences Inc	1.4%	1.7%	1,732,569	-37.2%	$95.6M
GHRSGh Research PLC	1.3%	—	3,333,334	—	$89.6M
COGTCogent Biosciences Inc	1.1%	0.8%	2,000,000	+100.0%	$77.4M
ATAIAtaibeckley Inc	1.1%	0.9%	14,417,442	+20.1%	$76.0M
UTHRUnited Therapeutics Corp Del	1.0%	—	123,616	—	$67.0M
AVTXAvalo Therapeutics Inc	1.0%	—	3,610,000	—	$66.7M
VRDNViridian Therapeutics Inc	1.0%	0.6%	3,592,740	+157.7%	$66.0M
CYTKCytokinetics	0.9%	1.9%	700,000	-49.1%	$59.6M
ALTAltimmune Inc	0.9%	—	19,250,000	—	$58.5M
PSNLPersonalis Inc	0.8%	—	4,000,000	—	$53.6M
ACRSAclaris Therapeutics Inc	0.7%	0.7%	9,345,000	+0.0%	$49.4M
CRMDCormedix Inc	0.7%	0.9%	6,274,076	+0.0%	$49.3M
WGSGenedx Holdings Corp	0.7%	—	700,000	—	$48.1M
HROWHarrow Inc	0.6%	—	969,000	—	$41.2M
CRVSCorvus Pharmaceuticals Inc Com	0.5%	0.8%	2,491,939	+0.0%	$37.2M
SLDBSolid Bioscience Inc.	0.5%	0.5%	3,565,062	+0.0%	$35.6M
BEAMBeam Therapeutics Inc	0.5%	—	1,000,000	—	$34.3M
DYNDyne Therapeutics Inc	0.5%	0.7%	1,500,000	-25.0%	$33.3M
IMMXImmix Biopharma Inc	0.4%	—	2,775,000	—	$28.6M
XFORX4 Pharmaceuticals Inc	0.4%	0.5%	5,878,757	-7.3%	$27.5M
STTKShattuck Labs Inc	0.4%	—	3,706,734	—	$25.7M
MNKDMannkind Corp	0.4%	—	6,000,000	—	$25.6M

What Deep Track Capital, LP bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +88.0% /yr; S&P 500 +20.1%
3 years: +33.8% /yr; S&P 500 +20.4%
5 years: +29.4% /yr; S&P 500 +13.0%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$6.8B	66
Q1 2026	$4.8B	62
Q4 2025	$4.4B	53
Q3 2025	$3.6B	56
Q2 2025	$3.1B	65
Q1 2025	$3.1B	69
Q4 2024	$2.7B	61
Q3 2024	$3.1B	69
Q2 2024	$3.3B	67
Q1 2024	$3.5B	65
Q4 2023	$2.9B	57
Q3 2023	$2.6B	62

Questions about Deep Track Capital, LP's portfolio

What stocks does Deep Track Capital, LP own?

Deep Track Capital, LP's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 66 positions worth $6.8B. The largest are Guardant Health Inc (GH) at 7.5%, Immunovant Inc (IMVT) at 5.3%, Structure Therapeutics F Unspo (GPCR) at 3.7%, Vaxcyte Inc (PCVX) at 3.7% and Alnylam Pharmaceuticals Inc (ALNY) at 3.7%.

What did Deep Track Capital, LP buy last quarter?

In Q2 2026, Deep Track Capital, LP added Veradermics Inc (MANE) (+300.0% shares), Biomarin Pharmaceutical Inc (BMRN) (+187.6% shares) and Viridian Therapeutics Inc (VRDN) (+157.7% shares), compared with its Q1 2026 filing.

What did Deep Track Capital, LP sell last quarter?

In Q2 2026, Deep Track Capital, LP cut from its top 50 Apellis Pharmaceuticals Inc (APLS), cut from its top 50 Centessa Pharmaceuticals PLC (CNTA), cut from its top 50 Bridgebio Pharma Inc (BBIO), cut from its top 50 Immunocore Hldgs PLC (IMCR), cut from its top 50 Terns Pharmaceuticals Inc (TERN), Cytokinetics (CYTK) (-49.1% shares), Mbx Biosciences Inc (MBX) (-37.2% shares) and Axsome Therapeutics, Inc. (AXSM) (-36.4% shares), compared with its Q1 2026 filing.

How has Deep Track Capital, LP's portfolio performed?

A portfolio copying Deep Track Capital, LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned +33.8% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +88.0% against +20.1%. Over 5 years: +29.4% a year against +13.0%.

When is Deep Track Capital, LP's next 13F filing due?

13F filings are due 45 days after each quarter ends. Deep Track Capital, LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Deep Track Capital, LP manage?

Deep Track Capital, LP reported $8.4B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $6.8B.